1. Acute Pancreatitis in a Patient Taking Semaglutide
- Author
-
Patel, Femina, Gan, Arnold, Chang, Karen, and Vega, Kenneth J
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Prevention ,Diabetes ,Digestive Diseases ,Obesity ,Clinical Research ,Autoimmune Disease ,Metabolic and endocrine ,Oral and gastrointestinal ,Good Health and Well Being ,abdominal pain ,acute pancreatitis ,glucagon-like peptide-1 receptor agonist ,post-cholecystectomy ,semaglutide ,Medical and Health Sciences ,Biomedical and clinical sciences ,Health sciences - Abstract
The Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) trial showed that semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), is effective in managing type 2 diabetes by stimulating insulin secretion and promoting weight loss. Though recent evidence suggests no increased risk of acute pancreatitis (AP) with subcutaneous semaglutide use, some studies report an increase in pancreatic inflammation with GLP-1 RAs. We present a case of AP in a patient recently started on subcutaneous semaglutide for type 2 diabetes. As GLP-1 RA use increases, clinicians should be aware of their potential to cause acute pancreatitis.
- Published
- 2023